Actively Recruiting
The Liver BIoBank Lombardia of Fatty Liver
Led by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Updated on 2025-11-18
2500
Participants Needed
1
Research Sites
917 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
NAFLD is most frequently linked to excess adiposity, insulin resistance and cardiometabolic risk factors, it has become the leading cause of liver disease worldwide, and is associated with increased mortality due to multiple causes. HFC has a strong genetic component and the investigators recently showed that it plays a causal role in determining progressive liver disease and insulin resistance. The genetic risk score predicting liver fat content (HFC-GRS) improves the stratification of liver related events, and the investigators have preliminary data on new common and rare variants that contribute to NAFLD susceptibility, and on a new non-invasive circulating biomarker associated with hepatic fat and lipotoxicity (Interleukin-32). However, no data are yet available on the causal role of hepatic fat on the procoagulant state associated with NAFLD, which could participate to liver damage and is a causal factor in atherothrombotic complications. The aim of the study is to examine the potential application of a precision medicine approach to the improvement of stratification of the risk of liver-related and cardiovascular thrombotic complications of hepatic fat accumulation (HFC) and non-alcoholic fatty liver disease (NAFLD), with a special focus on the role of procoagulant imbalance in mediating the at-risk phenotypes.
CONDITIONS
Official Title
The Liver BIoBank Lombardia of Fatty Liver
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Blood donors aged between 40 and 65 years
- Clinical diagnosis of overweight or obesity (BMI > 25 kg/m2)
- Increased fasting blood glucose (≥ 100 mg/dl), type 2 diabetes, dyslipidemia (triglycerides ≥ 150 mg/dl, HDL <45/55 in M/F), or arterial hypertension
- Part of a cohort with multiple metabolic risk factors
You will not qualify if you...
- Chronic degenerative diseases, except well-controlled hypertension and type 2 diabetes not requiring medication
- Blood donors younger than 40 or older than 65 years to avoid bias
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica
Milan, Milano, Italy, 20122
Actively Recruiting
Research Team
L
Luca Vittorio Carlo Valenti
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here